probucol has been researched along with Obesity in 4 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effect of Probucol in preventing fatty liver in monosodium-L-glutamate (MSG) treated obese mice and control mice fed a high fat diet." | 7.69 | Probucol prevents the progression of fatty liver in MSG obese mice. ( Kondo, M; Sakane, N; Umekawa, T; Yoshida, T; Yoshioka, K, 1995) |
| "We investigated the effect of Probucol in preventing fatty liver in monosodium-L-glutamate (MSG) treated obese mice and control mice fed a high fat diet." | 3.69 | Probucol prevents the progression of fatty liver in MSG obese mice. ( Kondo, M; Sakane, N; Umekawa, T; Yoshida, T; Yoshioka, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delaigle, AM | 1 |
| Senou, M | 1 |
| Guiot, Y | 1 |
| Many, MC | 1 |
| Brichard, SM | 1 |
| Yoshida, T | 1 |
| Yoshioka, K | 1 |
| Sakane, N | 1 |
| Umekawa, T | 1 |
| Kondo, M | 1 |
| Anikin, VV | 1 |
| Savin, VV | 1 |
| Lupanov, VP | 1 |
| Razygraev, RA | 1 |
| Miettinen, TA | 1 |
| Huttunen, JK | 1 |
| Naukkarinen, V | 1 |
| Strandberg, T | 1 |
| Vanhanen, H | 1 |
2 trials available for probucol and Obesity
| Article | Year |
|---|---|
[Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Biomarkers; Blood Glucose; Body Mass Index; Cardiac | 2000 |
Long-term use of probucol in the multifactorial primary prevention of vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cerebrovascular Disorders; Cholesterol, HDL; C | 1986 |
2 other studies available for probucol and Obesity
| Article | Year |
|---|---|
Induction of adiponectin in skeletal muscle of type 2 diabetic mice: In vivo and in vitro studies.
Topics: Adiponectin; Animals; Antioxidants; Body Weight; Cells, Cultured; Diabetes Mellitus, Type 2; DNA Pri | 2006 |
Probucol prevents the progression of fatty liver in MSG obese mice.
Topics: Animals; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholinesterases; Di | 1995 |